Form 24F-2NT T. Rowe Price Diversifie For: Dec 31
Tweet
Share
E-mailATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- T. ROWE PRICE LAUNCHES DYNAMIC EMERGING MARKETS BOND EXCHANGE TRADED FUND
- OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
- HIROMI ASAI's New Collection "Akatsuki: Before the Dawn" Arrives in Paris
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
